ライフサイエンスコーパス: prosthetic valve

1 morbillorum endocarditis in a patient with a prosthetic valve.

2 sthetic valve compared with the conventional prosthetic valve.

3 lve explant caused by PVR for Silzone-coated prosthetic valve.

4 the need for long-term anticoagulation or a prosthetic valve.

5 nt difference in survival related to type of prosthetic valve.

6 eart valve and 2620 other patients without a prosthetic valve.

7 whether the infection occurs in a native or prosthetic valve.

8 d abnormal FDG uptake around the site of the prosthetic valve.

9 lve replacement with tissue versus nontissue prosthetic valves.

10 ion as the etiology of obstructed mechanical prosthetic valves.

11 ing clinical status compared with mechanical prosthetic valves.

12 et thickening and periprosthetic leakage for prosthetic valves.

13 possible S aureus IE that involved native or prosthetic valves.

14 ves, 33 cases occurred, and in patients with prosthetic valves, 12 cases occurred.

15 etic valve, 29 of 285 (10%) and conventional prosthetic valve, 21 of 290 (7%, p = NS); the severity o

16 PVR was present in 50 valves: Silzone-coated prosthetic valve, 29 of 285 (10%) and conventional prost

17 s 17; P=0.046) and had a better knowledge of prosthetic valves (85% versus 68%; P=0.004).

18 66.1 years; 71.2% males), 414 (34.7%) had a prosthetic valve and 284 (23.8%) had a cardiac implanted

19 left ventricular assist device infection and prosthetic valve and pacemaker endocarditis.

20 Reviewers were blinded to the type of prosthetic valve and the demographic and clinical variab

21 in 23 patients presenting with 24 obstructed prosthetic valves and compared the findings to pathology

22 e diagnosis of endocarditis in patients with prosthetic valves and in those in whom TTE indicated an

23 hould be reserved only for patients who have prosthetic valves and in whom TTE is either technically

24 diagnosis of infective endocarditis (IE) in prosthetic valves and intracardiac devices is challengin

25 infections of prosthetic devices, including prosthetic valves and intravascular catheters, S. epider

26 ical differences, EE more frequently affects prosthetic valves and less frequently pacemakers/defibri

27 Recent developments guiding the choice of prosthetic valves and trends in in-hospital mortality ra

28 ed, 33% had community-acquired SAB, 8% had a prosthetic valve, and 11% a cardiac implantable electron

29 l mortality, correct positioning of a single prosthetic valve, and proper prosthetic valve performanc

30 s clinical indications with a larger role in prosthetic valves, and cardiac devices particularly with

31 lied to guide the design and implantation of prosthetic valves, and have potential clinical utility a

32 Prosthetic valve aortic regurgitation (central plus para

33 anticoagulation for atrial fibrillation, and prosthetic valves are vital therapeutic adjuncts.

34 TAVR patients had larger prosthetic valve area (1.7 cm(2) vs. 1.2 cm(2), p<0.001)

35 Previous studies indicate that a minimal prosthetic valve area index (VAI) of > or = 0.9 cm2/m2 f

36 VAI was calculated from the ratio of prosthetic valve area to body surface area for each pati

37 Adding abnormal FDG uptake around the prosthetic valve as a new major criterion significantly

38 303 episodes of left-sided suspected IE (188 prosthetic valves/ascending aortic prosthesis and 115 na

39 tensity of the mass obstructing a mechanical prosthetic valve can help differentiate pannus formation

40 nce or severity of PVR in the Silzone-coated prosthetic valve compared with the conventional prosthet

41 With these developments, prosthetic valve complications, including prosthetic val

42 Prosthetic valves currently used in children lack the ab

43 There was a temporal increase in prosthetic valve Doppler mean gradient (baseline versus

44 endations are provided for the evaluation of prosthetic valve (dys)function.

45 At 5 years, 3 patients (3.4%) had moderate prosthetic valve dysfunction (moderate transvalvular reg

46 re recruited into 2 cohorts with and without prosthetic valve dysfunction and underwent in vivo contr

47 14 years) patients with suspected mechanical prosthetic valve dysfunction assessed by transesophageal

48 uishing pannus and thrombus in patients with prosthetic valve dysfunction is essential for the select

49 company the high-shear state associated with prosthetic valve dysfunction.

50 unctive value in the difficult assessment of prosthetic valve dysfunction.

51 es amenable to thrombolysis in patients with prosthetic valve dysfunction.

52 follow-up shows no evidence of restenosis or prosthetic valve dysfunction.

53 ne-coated prosthetic valve or a conventional prosthetic valve; early clinical reports showed higher r

54 Prosthetic valve endocarditis (PVE) after TAVI is a seri

55 the prognostic value of (18)F-FDG PET/CT in prosthetic valve endocarditis (PVE) and native valve end

56 diagnosis of infective endocarditis (IE) in prosthetic valve endocarditis (PVE) including IE after t

57 Prosthetic valve endocarditis (PVE) is a major infectiou

58 Prosthetic valve endocarditis (PVE) is a rare but critic

59 Prosthetic valve endocarditis (PVE) is associated with s

60 but can be inconclusive in patients in whom prosthetic valve endocarditis (PVE) is suspected.

61 Among 302 episodes of prosthetic valve endocarditis (PVE), 1-year mortality wa

62 decades, there have been numerous changes in prosthetic valve endocarditis (PVE), currently affecting

63 In non-operated prosthetic valve endocarditis (PVE), long term outcome i

64 In nonoperated prosthetic valve endocarditis (PVE), long-term outcome i

65 fampin-based combinations for staphylococcal prosthetic valve endocarditis (PVE).

66 tomography ((18)F-FDG PET/CT) for diagnosing prosthetic valve endocarditis (PVE).

67 ed in the subgroups of patients with NVE and prosthetic valve endocarditis (PVE)/ascending aortic pro

68 es of infections of prosthetic heart valves (prosthetic valve endocarditis [PVE]) and an increasingly

69 Prosthetic valve endocarditis accounts for a high percen

70 study including 20 patients with IE (10 with prosthetic valve endocarditis and 10 with native valve e

71 diagnostic workup of patients with suspected prosthetic valve endocarditis and cardiac device infecti

72 13, over 100 cases of Mycobacterium chimaera prosthetic valve endocarditis and disseminated disease w

73 We report a case of R. mucilaginosa prosthetic valve endocarditis and review the literature

74 value, TEE is essential in the evaluation of prosthetic valve endocarditis and the paravalvular compl

75 e describe a case of bacteremia and possibly prosthetic valve endocarditis by this organism in a noni

76 lthough this difference was mainly driven by prosthetic valve endocarditis cases (3.23 [2.02-3.86]; P

77 the case of a 75-year-old German woman with prosthetic valve endocarditis due to Bartonella washoens

78 Prosthetic valve endocarditis is an uncommon manifestati

79 ococcus epidermidis, 20 skin isolates and 19 prosthetic valve endocarditis isolates were characterize

80 e patients aged between 49 and 64 years with prosthetic valve endocarditis or vascular graft infectio

81 s for PET were oncology (n=26), suspicion of prosthetic valve endocarditis subsequently excluded (n=1

82 we aim to characterize the manifestations of prosthetic valve endocarditis using representative case

83 The analysis of prosthetic valve endocarditis versus the 20 controls sho

84 Prosthetic valve endocarditis was a significant predicto

85 For prosthetic valve endocarditis with small vegetations, th

86 rs; 96 men [91.4%]; 93 patients [88.6%] with prosthetic valve endocarditis) were identified and inclu

87 hom 81% had congenital heart disease, 8% had prosthetic valve endocarditis, and 5% had rheumatic hear

88 )F]FDG PET/CT for native valve endocarditis, prosthetic valve endocarditis, and controls.

89 s, prosthetic valve complications, including prosthetic valve endocarditis, are increasingly encounte

90 rn approach to cardiac imaging in native and prosthetic valve endocarditis, as well as cardiac implan

91 For all patients with prosthetic valve endocarditis, bioprosthetic valves are

92 cently acknowledged as a diagnostic tool for prosthetic valve endocarditis, but its specificity is li

93 Propionibacterium acnes bacteremia and late prosthetic valve endocarditis, complicated by an aortic

94 cluded symptoms at presentation, presence of prosthetic valve endocarditis, laboratory test results a

95 sdiagnosed IE particularly in the setting of prosthetic valve endocarditis, paravalvular extension of

96 no reports of operative (30-day) mortality, prosthetic valve endocarditis, renal failure necessitati

97 rion for the diagnosis of device-related and prosthetic valve endocarditis, that addition has not bee

98 IE after TAVR is recognized as a subtype of prosthetic valve endocarditis, this condition represents

99 th; demographic and clinical findings (i.e., prosthetic valve endocarditis, thromboembolism, bleeding

100 l nervous system shunt infections, native or prosthetic valve endocarditis, urinary tract infections,

101 ed when interpreting FDG PET/CT in suspected prosthetic valve endocarditis, with specific attention t

102 degeneration, nonstructural dysfunction, or prosthetic valve endocarditis.

103 with infective endocarditis, also in case of prosthetic valve endocarditis.

104 ery, aortocavitary fistula, heart block, and prosthetic valve endocarditis.

105 in some cases of apparently culture-negative prosthetic valve endocarditis.

106 describe a case of Mycobacterium mageritense prosthetic valve endocarditis.

107 and pulmonary atresia, and 4 of 54 (8%) with prosthetic valve endocarditis.

108 Excluding those patients who had initial prosthetic valve explant, the two-year echocardiographic

109 PVE is an established mechanism of prosthetic valve failure post-SAVR and TAVR with unclear

110 Signs of moderate prosthetic valve failure were observed in 3.4% of patien

111 vely evaluated the diagnostic outcome of 113 prosthetic valves from 105 patients with suspected PVE,

112 To review the current literature on prosthetic valve function and para-valvular regurgitatio

113 1 month, and 2 months demonstrated excellent prosthetic valve function with a low transvalvular gradi

114 e all-cause mortality and temporal change in prosthetic valve gradient and clinical indices of diseas

115 However, there was a significant increase in prosthetic valve gradient within 10 years of follow-up,

116 , especially in the challenging scenarios of prosthetic valve IE and cardiac implantable electronic d

117 was markedly lower for native valve IE than prosthetic valve IE and cardiac implantable electronic d

118 remains diagnostically imperfect in cases of prosthetic valve IE or cardiac implantable electronic de

119 were adjudicated as having IE; 111 (19%) had prosthetic valve IE, and 48 (8%) had a cardiac implantab

120 of IE and its subgroups of native valve IE, prosthetic valve IE, and cardiac implantable electronic

121 Native and prosthetic valve IE, infections relating to cardiac impl

122 and specificity 0.98 (0.95-0.99, 34.4%); for prosthetic valve IE: sensitivity 0.86 (0.81-0.89, 60.0%)

123 t occurs in 5-17% of patients after surgical prosthetic valve implantation.

124 Finally, patients with prosthetic valves implanted surgically or by the transca

125 thrombosis occurred in 24 (6%) women, and a prosthetic valve in mitral position was associated with

126 r; 95% CI: 1.03-1.06 per year; P < 0.001), a prosthetic valve in other positions (HR: 2.1; 95% CI: 1.

127 The microbial etiology of prosthetic valve infective endocarditis (PVE) can be dif

128 on the outcome of Staphylococcus aureus (SA) prosthetic valve infective endocarditis (PVIE) is unreso

129 lling 4166 patients with definite native- or prosthetic-valve infective endocarditis from 61 centers

130 re routine surveillance within 3 years after prosthetic valve insertion (73 [17.1%]), routine surveil

131 her rates of prior heart disease, aortic and prosthetic valve involvement, nosocomial acquisition, me

132 The effective orifice area (EOA) of a prosthetic valve is superior to transvalvular gradients

133 in the assessment of cardiac sarcoidosis and prosthetic valves is also provided.

134 eciding between bioprosthetic and mechanical prosthetic valves is challenging because long-term survi

135 nction of thrombus from pannus on obstructed prosthetic valves is essential because thrombolytic ther

136 the percentage of patients with at least one prosthetic valve leaflet with grade 3 or higher motion r

137 At least one prosthetic valve leaflet with grade 3 or higher motion r

138 There is a need for strategies to improve prosthetic valve longevity, which in turn may improve ou

139 tic valves (Bio_AVR group) versus mechanical prosthetic valves (Mech_AVR group).

140 Abnormal prosthetic valve motion was detected by TEE in all cases

141 o underwent echocardiography (Silzone-coated prosthetic valve, n = 285 and conventional prosthetic va

142 d prosthetic valve, n = 285 and conventional prosthetic valve, n = 290), 59% had prosthetic aortic va

143 and when valve involvement (especially of a prosthetic valve) needs to be excluded during febrile ep

144 tients with IE after TAVI, IE after non-TAVI prosthetic valve (nTPV), and native valve IE.

145 Prosthetic valve obstruction is a rare but potentially l

146 elevated mean LA pressures in the absence of prosthetic valve obstruction or regurgitation.

147 tion of patients for thrombolytic therapy of prosthetic valve obstruction.

148 andomized to receive either a Silzone-coated prosthetic valve or a conventional prosthetic valve; ear

149 ents admitted to our hospital with suspected prosthetic valve or cardiac device IE between November 2

150 (1.8%) had endocarditis (20 native valve, 29 prosthetic valve or device) due to non-HACEK, gram-negat

151 odified DC in patients with suspected IE and prosthetic valves or cardiac devices.

152 infective endocarditis (IE) in patients with prosthetic valves or implantable devices.

153 of cases in PWID involve left-sided valves, prosthetic valves, or are caused by microorganisms other

154 alve (P<0.001) and 78% of patients without a prosthetic valve (P<0.001).

155 (P<0.001), and in 4.9% of patients without a prosthetic valve (P<0.001).

156 (P=1.000), and in 0.2% of patients without a prosthetic valve (P=0.025).

157 coated prosthetic valve vs. 94% conventional prosthetic valve, p = NS).

158 ing of a single prosthetic valve, and proper prosthetic valve performance.

159 Association functional class I/II with good prosthetic valve performance.

160 e kidney injury, vascular complications, and prosthetic valve performance.

161 blood culture bottles, native valve disease, prosthetic valve, previous IE, and cardiac device.

162 inconclusive, particularly in patients with prosthetic valves (PVs) and implantable cardiac electron

163 ing aorta by using a graft with or without a prosthetic valve, reconstruction with a composite artifi

164 end point at 30 days due to higher rates of prosthetic valve regurgitation and acute kidney injury.

165 r vascular complications, moderate or severe prosthetic valve regurgitation, and conduction system di

166 quiring repeat procedure, moderate or severe prosthetic valve regurgitation, or prosthetic valve sten

167 ay be a reasonable alternative to mechanical prosthetic valve replacement in patients aged 50 to 69 y

168 iabetes, renal failure, aortic stenosis, and prosthetic valve replacement.

169 adient >=5 mm Hg or area <=1.5 cm(2) and [2] prosthetic valve: resting mean MV gradient >=5 mm Hg or

170 icular function, urgent or emergency status, prosthetic valve size < or = 23 mm and hospital activity

171 5% CI 1.14 to 11.89), and increased ratio of prosthetic valve size to patient weight (relative risk 1

172 Reasons for second MVR were prosthetic valve stenosis 24 (83%), thrombosis 4 (14%),

173 or severe prosthetic valve regurgitation, or prosthetic valve stenosis within 30 days of the procedur

174 rtic root enlargement, supra-annular stented prosthetic valves, stentless bioprosthesis, and suturele

175 patients with pre-existing cardiac lesions, prosthetic valves, stents, coronary bypass grafts, and i

176 Compared with nontissue prosthetic valves, the use of tissue valves was not pred

177 Prosthetic valve thrombosis (PVT) is one of the life-thr

178 stratify patients undergoing thrombolysis of prosthetic valve thrombosis (PVT).

179 Prosthetic valve thrombosis during pregnancy is life-thr

180 consecutive women in 25 pregnancies with 28 prosthetic valve thrombosis episodes (obstructive, n=15;

181 rombolytic success rate for the treatment of prosthetic valve thrombosis in pregnant women.

182 e plasminogen activator for the treatment of prosthetic valve thrombosis in pregnant women.

183 of aspirin, use of fibrinolytic therapy for prosthetic valve thrombosis, and management of paravalvu

184 venous access device thrombosis, mechanical prosthetic valve thrombosis, left ventricular assist dev

185 s therefore recommended in the management of prosthetic valve thrombosis.

186 first-line therapy in pregnant patients with prosthetic valve thrombosis.

187 ereafter, the authors: 1) review the data on prosthetic valve thrombosis; 2) discuss the pathophysiol

188 of acute insertion of a second transcatheter prosthetic valve (TV) within the first (TV-in-TV) or tra

189 gestive heart failure, native valve disease, prosthetic valve type, preoperative catheterization data

190 Each prosthetic valve underwent cultural diagnostics and was

191 equency of valve repair, higher frequency of prosthetic valve usage in elderly patients, and lower ad

192 24-month event-free rate: 93% Silzone-coated prosthetic valve vs. 94% conventional prosthetic valve,

193 A mitral prosthetic valve was identified as a predictor for valve

194 he videointensity of the mass to that of the prosthetic valve, was lower in the thrombus group (0.46+

195 Mechanical prosthetic valves were associated with lower risk of reo

196 late might be reconsidered for patients with prosthetic valves, who require life-long anticoagulation

197 technology that allows for implantation of a prosthetic valve without open heart surgery.